A detailed history of Royal Bank Of Canada transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,375 shares of MDGL stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,375
Previous 2,511 233.53%
Holding current value
$1.82 Million
Previous $670,000 250.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $1.13 Million - $1.71 Million
5,864 Added 233.53%
8,375 $2.35 Million
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $720,439 - $1.19 Million
-4,204 Reduced 62.61%
2,511 $670,000
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $540,957 - $1.07 Million
4,493 Added 202.21%
6,715 $1.55 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $1.34 Million - $2.07 Million
-9,166 Reduced 80.49%
2,222 $324,000
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $322,742 - $493,896
-1,583 Reduced 12.2%
11,388 $2.63 Million
Q1 2023

May 15, 2023

SELL
$231.06 - $307.08 $41,359 - $54,967
-179 Reduced 1.36%
12,971 $3.14 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $150,062 - $762,107
2,570 Added 24.29%
13,150 $3.82 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $5,027 - $6,599
83 Added 0.79%
10,580 $688,000
Q2 2022

Aug 15, 2022

SELL
$58.04 - $100.2 $37,842 - $65,330
-652 Reduced 5.85%
10,497 $751,000
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $109,600 - $199,806
-1,961 Reduced 14.96%
11,149 $1.09 Million
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $378,844 - $497,986
5,237 Added 66.52%
13,110 $1.11 Million
Q3 2021

Nov 15, 2021

BUY
$78.35 - $105.02 $13,632 - $18,273
174 Added 2.26%
7,873 $629,000
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $748,342 - $1.06 Million
7,699 New
7,699 $751,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.72B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.